### Appendix 1: Complete patient management and individual survival for patients with secondary neoplasms of the bladder from each primary malignancy

#### Prostate

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|-----------------|-----------------------------|---------|---------------------------------|-------------|-------|---------|---------------------------------|-------------|-------|----------------|
| 1       | 0                                                  | 1  | Direct          | Bone, Lymph                 | n/a     | n/a                             | n/a         | n/a  | -       | Docetaxel (3 cycles)            | 21 Gy in three fractions | ADT   | 654            |
| 2       | 4748                                               | 3  | Direct          | Bone, Lymph nodes           | n/a     | n/a                             | 70 Gy in 35 fractions | ADT  | -       | Docetaxel (6 cycles)            | 21 Gy in three fractions | ADT   | 97             |
| 3       | 1693                                               | 1  | Direct          | Bone, Lymph                 | Open Prostatectomy | n/a     | 70 Gy in 35 fractions           | n/a         | -    | -       | Docetaxel (6 cycles)            | 21 Gy in three fractions | ADT   | 1250           |
| 4       | 0                                                  | 3  | Direct          | Lymph, bone                 | n/a     | n/a                             | n/a         | n/a  | -       | -                               | 21 Gy in three fractions | ADT   | 77             |
| 5       | 0                                                  | 2  | Direct          | Bone, Lymph, Lung           | n/a     | n/a                             | n/a         | n/a  | -       | -                               | 21 Gy in three fractions | ADT   | 632            |
| 6       | 0                                                  | 4  | Direct          | Lymph                       | n/a     | n/a                             | n/a         | n/a  | -       | -                               | ADT         | 210              |
| 7       | 4388                                               | 2  | Direct          | Lymph                       | n/a     | n/a                             | 70 Gy in 35 fractions | n/a  | -       | Docetaxel (6 cycles)            | ADT         | 1489             |
| 8       | 0                                                  | 2  | Direct          | Lymph, bone                 | n/a     | n/a                             | n/a         | n/a  | -       | Docetaxel (6 cycles)            | 21 Gy in three fractions | ADT   | 1407           |
| 9       | 0                                                  | 1  | Direct          | Lymph, bone                 | n/a     | n/a                             | n/a         | n/a  | -       | Docetaxel (6 cycles)            | 21 Gy in three fractions | ADT   | 961            |
| 10      | 0                                                  | 3  | Direct          | Lymph                       | n/a     | n/a                             | n/a         | n/a  | -       | -                               | ADT         | 210              |
| 11      | 948                                                | 3  | Direct          | Lymph, Bone, Lung           | n/a     | n/a                             | 70 Gy in 35 fractions | ADT  | -       | -                               | ADT         | 154              |
| 12      | 0                                                  | 3  | Direct          | Lymph, bone, liver          | n/a     | n/a                             | n/a         | n/a  | -       | -                               | ADT         | 114              |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary prostate malignancy. ADT: androgen deprivation therapy.

#### Colorectal

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|-----------------|-----------------------------|---------|---------------------------------|-------------|-------|---------|---------------------------------|-------------|-------|----------------|
| 1       | 1342                                               | 2  | Distant         | Lymph, liver                | Extended Hemicolectomy | 6 cycles adjacent Oxaliplatin/Capecitabine | -           | -    | -       | 6 cycles FOLFIRI and Bevacizumab: 3 cycles (Cetuximab 1 cycle TAS-102 | -           | -    | 260            |
| 2       | 0                                                  | 1  | Direct          | Lymph, lung, liver, peritoneum | -      | -                              | -           | -    | -       | Anterior resection + TAH + BSO + cystectomy | FOLFIRI     | 25 Gy in 5 fractions | bevacizumab | 1286           |
| 3       | 0                                                  | 1  | Direct          | Lymph, liver                | -      | -                              | -           | -    | -       | Radical cysto-prostatectomy + harnms | 6 cycles Raltrexed + Oxaliplatin | -    | 627            |
| 4       | 0                                                  | 3  | Direct          | Lymph, lung, liver, bone     | -      | -                              | -           | -    | -       | -                               | -           | -    | 99             |
| 5       | 2979                                               | 3  | Distant         | Lymph, lung                 | Anterior Resection | 25 Gy in 5 fractions | -           | -    | -       | Raltrexed, Oxaliplatin 6 cycles | -           | -    | 403            |
| 6       | 321                                                | 2  | Direct          | Lymph                       | Hemicolectomy | FOLFOX 6 cycles        | -           | -    | -       | -                               | FOLFIRI 4 cycles          | -    | 341            |
| 7       | 62                                                 | 2  | Direct          | Lymph, liver                | Hemicolectomy | Oxaliplatin 6 cycles    | -           | -    | -       | -                               | fluorouracil/5-fluorouracil acid 6 cycles | -    | 543            |
| 8       | 81                                                 | 2  | Direct          | Lymph, peritoneum, liver    | anterior reaction + TAH + BSO | Oxaliplatin and Capecitabine 6 cycles | short-course radiotherapy | - | - | 6 cycles FOLFIRI and Bevacizumab: 20 Gy in 5 fractions | - | - | 720 |
| 9       | 0                                                  | 3  | Direct          | Lymph                       | -      | -                              | -           | -    | -       | -                               | -           | -    | 84             |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary colorectal malignancy. FOLFOX: Folinic acid/5-fluorouracil (5FU)/Oxaliplatin, FOLFIRI: Folinic acid/5-fluorouracil (5FU)/Irinotecan, TAS-102: Trifluridine/tipiracil. TAH + BSO: Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.

#### Ovary

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|-----------------|-----------------------------|---------|---------------------------------|-------------|-------|---------|---------------------------------|-------------|-------|----------------|
| 1       | 0                                                  | 2  | Direct          | Lymph, peritoneum, liver    | -      | -                              | -           | -    | -       | TAH+ BSO+ Omentectomy + partial cystectomy | paclitaxel and carboplatin + gemcitabine 4 cycles | -    | 695            |
| 2       | 143                                                | 1  | Distant         | Lymph, peritoneum           | TAH + BSO | Carboplatin + paclitaxel + Avastin 6 cycles | -           | -    | -       | -                               | -           | -    | 410            |
| 3       | 0                                                  | 2  | Direct          | Lymph, peritoneum           | -      | -                              | -           | -    | -       | -                               | Avastin and paclitaxel 1 cycle | -    | 369            |
| 4       | 0                                                  | 2  | Direct          | Lymph, lung                 | -      | -                              | -           | -    | -       | -                               | -           | -    | 127            |
| 5       | 411                                                | 3  | Distant         | Lymph, lungs, liver         | TAH + BSO | carboplatin and doceaxel 6 cycles | -           | -    | -       | -                               | -           | -    | 81             |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary ovarian malignancy. TAH + BSO: Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.
## Cervical Cancer

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|----------------|-----------------------------|---------|-------------------------------|-------------|-------|---------|-------------------------------|-------------|-------|-----------------|
| 1       | 241                                                | 3   | Direct         | Lymph, Liver                | -       | Cisplatin 2 cycles            | 20 Gy 5 fractions | -     | -       | -                            | -           | -     | 125             |
| 2       | 324                                                | 2   | Direct         | Lymph, rectum               | TAH + BSO | Cisplatin 6 cycles           | 20 Gy 5 fractions | -     | -       | -                            | -           | -     | 236             |
| 3       | 0                                                  | 3   | Direct         | Lymph, rectum               | -       | -                             | -            | -     | -       | -                            | -           | -     | 162             |
| 4       | 0                                                  | 3   | Direct         | Lymph, rectum, Liver        | -       | -                             | -            | -     | -       | -                            | -           | -     | 134             |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary cervical malignancy. TAH + BSO: Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.

## Breast Cancer

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|----------------|-----------------------------|---------|-------------------------------|-------------|-------|---------|-------------------------------|-------------|-------|-----------------|
| 1       | 1869                                               | 1   | Distant        | Bone, Lymph, Liver, Brain, Lung | Mastectomy | FEC + paclitaxel 6 cycles | Radiotherapy trastuzumab | -     | docetaxel | -                             | -           | -     | 241             |
| 2       | 1211                                               | 2   | Distant        | Lymph, Bone, Liver          | Mastectomy | FEC + Docetaxel 6 cycles | Radiotherapy | -     | -       | -                            | -           | -     | 162             |
| 3       | 481                                                | 2   | Distant        | Lymph, Liver, Lung          | Mastectomy | FEC + Docetaxel 6 cycles | Radiotherapy Trastuzumab | -     | Paclitaxel | -                             | -           | -     | 369             |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary breast malignancy. FEC- 5 fluorouracil (5FU) Epirubicin, Cyclophosphamide.

## Lymphoma

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|----------------|-----------------------------|---------|-------------------------------|-------------|-------|---------|-------------------------------|-------------|-------|-----------------|
| 1       | 146                                                | 3   | hematopoietic  | Spleen, Liver               | -       | -                             | -            | -     | -       | -                            | -           | -     | 98              |
| 2       | 431                                                | 2   | hematopoietic  | Bone marrow, Lung           | -       | -                             | -            | -     | -       | -                            | -           | -     | 145             |
| 3       | 368                                                | 2   | hematopoietic  | Lung, Liver                 | -       | CHOP + Methotrexate           | -            | -     | -       | -                            | -           | -     | 278             |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary lymphoma. CHOP- Cyclophosphamide, Doxorubicin (Adriamycin), Vincristine (Oncovin), Prednisolone.

## Renal Cell Carcinoma

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|----------------|-----------------------------|---------|-------------------------------|-------------|-------|---------|-------------------------------|-------------|-------|-----------------|
| 1       | 744                                                | 2   | Distant        | Liver, Lung                 | Radical Nephrectomy | -       | -                             | -            | -     | -       | -                            | -           | -     | 326             |
| 2       | 3868                                               | 0   | Distant        | Lung                        | Radical Nephrectomy | -       | -                             | -            | -     | -       | -                            | -           | -     | 1383            |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary renal malignancy. TKI- Tyrosine Kinase Inhibitor.

## Gastric Cancer

| Patient | Time between primary diagnosis and secondary (days) | PS | Method of spread | Other Mets/extent of disease | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Surgery | Chemotherapy (Number of cycles) | Radiotherapy | Other | Survival (Days) |
|---------|----------------------------------------------------|----|----------------|-----------------------------|---------|-------------------------------|-------------|-------|---------|-------------------------------|-------------|-------|-----------------|
| 1       | 0                                                  | 2   | Distant        | Liver, Bone                 | -       | -                             | -            | -     | -       | -                            | -           | -     | 98              |
| 2       | 0                                                  | 3   | Distant        | Liver, Peritonium, Lung     | -       | -                             | -            | -     | -       | -                            | -           | -     | 31              |

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary gastric malignancy.